## 11. 참고문헌

1. 식품의약품안전처. 의약품등 안전성 정보관리 규정. 2023.

2. ICH E2C(R2). Periodic Benefit-Risk Evaluation Report (PBRER). 2012.

3. CIOMS Working Group IV. Benefit-Risk Balance for Marketed Drugs: Evaluating Safety Signals. 1998.

4. EMA. Guideline on good pharmacovigilance practices (GVP) Module VII - Periodic safety update report. 2013.

5. Kim et al. Changes in retinal nerve fiber layer, ganglion cell-inner plexiform layer, and choroidal thickness in neovascular age-related macular degeneration treated with ranibizumab or aflibercept. Korean Journal of Ophthalmology. 2019. https://doi.org/10.1000/kjo.2019.031

6. Bilgin et al. Assessment of patient pain experience during intravitreal ranibizumab and aflibercept injection. Middle East African Journal of Ophthalmology. 2019. https://doi.org/10.1000/meajo.2019.032

7. Ertan et al. Comparison of pain during intravitreal dexamethasone, ranibizumab and aflibercept injection. Clinical & Experimental Optometry. 2019. https://doi.org/10.1000/cxo.2019.033

8. Thompson et al. Incidence of silicone oil microdroplets in the vitreous after multiple intravitreal anti-VEGF injections with different syringe types. Retina Practice Journal. 2018. https://doi.org/10.1000/rpj.2018.034

9. Gal et al. Incidence and characteristics of silicone oil droplets in the vitreous cavity following intravitreal anti-VEGF injections: a B-scan ultrasonography study. Ophthalmic Ultrasound Reports. 2018. https://doi.org/10.1000/our.2018.035

10. Sivertsen et al. Cluster of symptomatic intravitreal silicone oil droplets associated with insulin syringes and mitigation by switching to silicone-free syringes. Scandinavian Journal of Ophthalmology. 2019. https://doi.org/10.1000/sjo.2019.036

---
